Understanding the factors contributing to tumor initiation, progression and evolution is of paramount significance. Among them, wild-type p53-induced phosphatase 1 (Wip1) is emerging as an important oncogene by virtue of its negative control on several key tumor suppressor pathways. Originally discovered as a p53-regulated gene, Wip1 has been subsequently found amplified and more recently mutated in a significant fraction of human cancers including breast tumors. Recent development in the field further uncovered the utility of anti-Wip1-directed therapies in delaying tumor onset or in reducing the tumor burden. Furthermore, Wip1 could be an important factor that contributes to tumor heterogeneity, suggesting that its inhibition may decrease the rate of cancer evolution. These effects depend on several signaling pathways modulated by Wip1 phosphatase in a spatial and temporal manner. In this review we discuss the recent development in understanding how Wip1 contributes to tumorigenesis with its relevance to breast cancer.
INTRODUCTION
Preserving genome integrity is vital to cellular homeostasis as it ensures inheritance of the correct genetic information and thus preserves normal physiological functions. During the course of life, single cells are constantly challenged by DNA damage from both endogenous and exogenous factors. These factors include metabolic products, reactive oxygen species, ultraviolet light and environmental mutagens, among many others. To counter the damage inflicted on the genome, cells have developed surveillance mechanisms that monitor genotoxic stress and set off an orchestrated response that activates cell cycle checkpoints, senescence, apoptosis and DNA repair. This multilayered response is collectively termed the DNA damage response (DDR). 1 If left unrepaired, DNA damage impairs essential DNA metabolic processes, such as DNA replication, transcription and recombination, and this ultimately leads to the generation of mutations, deletions, fusions or even chromosomal rearrangements and chromosomal loss, all of which are commonly observed in human cancer. 2 Loss of genomic integrity owing to altered or impaired DDR gene function may increase the risk that cells accumulate mutations in genes that promote cancer development. Germ line polymorphisms and mutations in DDR genes predispose organisms to cancer development, and somatic mutations and epigenetic silencing of DDR genes is common in multiple human cancers. These observations suggest that DDR genes act as tumor suppressors. An altered DDR leads not only to a predisposition to earlier tumor onset but also alters the sensitivity of tumors to chemotherapy and contributes to the development of drug resistance. [3] [4] [5] Numerous DDR proteins have been identified and the significance of their regulation by posttranslational modifications such as phosphorylation, ubiquitylation and sumoylation has been widely appreciated. [6] [7] [8] [9] One of the key components in the DDR network is the wild-type p53-induced phosphatase 1 (Wip1), a member of the PP2C family of Ser/Thr protein phosphatases. Wip1 is encoded by the gene PPM1D, which was first identified as a p53 target gene induced by different types of DNA damage, including ionizing irradiation. 10 Human PPM1D encodes a 605-amino acid protein containing a central phosphatase catalytic domain and a C-terminal domain with a nuclear localization signal. In response to DNA damage, Wip1 dephosphorylates several proteins in the DDR/checkpoint pathways, including Atm, p53, Chk1, Chk2, Mdm2, Mdm4 and p38 MAPK, establishing oscillating negative feedback loops that provide stringent conditions for cell cycle reentry when DNA damage is repaired. [11] [12] [13] [14] [15] [16] [17] [18] Wip1 dephosphorylates proteins that are directly involved in sensing and repairing DNA damage, such as Atm, Chk2, γ-H2AX, XPA, XPC and UNG2; Wip1 thus directly or indirectly suppresses homologous recombination repair, non-homologous end joining-mediated repair and the nucleotide excision repair and base-excision repair processes. [19] [20] [21] [22] [23] [24] Furthermore, alterations in Wip1 expression can abrogate the homeostatic balance maintained by the Wip1-p38 MAPK pathway, leading to changes in the expression of tumor suppressor CDKN2A (INK4A, p16). 25, 26 Wip1 is also involved in a negative feedback loop by downregulating NF-κB functions under inflammatory stress conditions via p38 MAPK and the RelA (p65) subunit of NF-κB. 27, 28 In addition, Wip1 was recently reported to inhibit both DNA methylation and is involved in the epigenetic control of expression of heterochromatin-associated retro elements, such as LINE-1 and HERV-H. 29 The function of Wip1 as a negative regulator of several tumor suppressor genes and as a modulator of the epigenetic state of the genome suggest its oncogenic potential and that it may have a role in the development of new mutations during tumorigenesis. Consistent with Wip1's function as an oncogene, PPM1D amplification and/or overexpression have been observed in numerous tumors, including breast cancer, ovarian clear cell adenocarcinoma, neuroblastoma, medulloblastoma, pancreatic adenocarcinoma, gastric carcinoma, papillary thyroid cancer, hepatocellular carcinoma, colorectal, prostate cancer and bladder transitional cell carcinomas. 26, More recently, gain-of-function Wip1 mutations have been identified in primary human cancers, further supporting the idea that inhibition of Wip1 may have an important therapeutic role in suppressing tumor growth and evolution. [52] [53] [54] [55] In this respect, several chemical inhibitors have been recently identified including orally active, allosteric inhibitors of Wip1. 56 Among the many human cancers that may be affected by Wip1, mammary gland cancers have been studied most intensively in terms of the role of Wip1 and are thus the focus of this review.
WIP1 IN NORMAL MAMMARY GLAND DEVELOPMENT
Mammary gland epithelium consists of an outer basal layer of primarily contractile myoepithelial cells plus an inner luminal layer that includes both steroid receptor-positive and -negative cells. The development of the mammary gland is tightly controlled by the sex hormones estrogen and progesterone, both of which trigger the production of paracrine factors by steroid receptorpositive cells. This in turn induces the proliferation of steroid receptor-negative cells. 57 During the initial phases of pregnancy, there is a massive expansion of the alveolar cell population in a process called lobulo-alveologenesis. This is followed later in pregnancy by terminal differentiation of the alveolar cells. 58, 59 Both processes are strictly dependent on prolactin signaling, as mutant proteins in the prolactin receptor-Jak2-Stat5 signaling cascade lead to defects in alveolar development. [60] [61] [62] In turn, Stat5 is essential for the expression of milk-producing genes. 63 Analysis of mouse mammary gland development reveals that in the absence of Wip1 there is a delay in alveolar development in response to the peptide hormone prolactin. Progesterone, together with prolactin, is essential for triggering the expansion of the alveolar cell population during lobulo-alveolegenesis. [64] [65] [66] In the virgin stage, only steroid receptor-positive hormonesensing cells can activate STAT5 in response to low levels of prolactin, and this activation is dependent on the presence of Wip1. 67 In addition, hormone-sensing cells require Wip1 for activation of Erk and Stat5 in response to Erbb2 activation. In contrast, Erbb2 activation in alveolar progenitor cells is Wip1 independent. Furthermore, in the absence of Wip1, the number of hormone-sensing cells in the mammary epithelium is reduced compared with the number in wild-type mice. 67 Taken together, these data suggest a role for Wip1 in maintaining paracrine stimulation of alveolar cell proliferation during normal development and potentially during cancer initiation and progression.
WIP1 AS AN ONCOGENE IN MAMMARY GLAND TUMORIGENESIS
Human breast cancer comprises tumors with complex histopathological and genetic features. Breast tumors are highly heterogeneous, involving the simultaneous transmission and processing of many signals between multiple cell types in a microenvironment that varies over time. [68] [69] [70] Cellular variation often includes diverse genetic populations within the same cell type. By sequencing single cells in high-grade (III) ductal carcinomas, Navin et al. 71 found four major genetically diverse tumorigenic cell subpopulations. Creating further complexity, tumor cells accounted for only a fraction of the tumor, whereas majority of the cells were normal cells (largely leukocytes). This ultimately poses a major challenge to successful cancer treatment, as the treatment needs to target multiple processes, such as proliferation, differentiation and cell death, in multiple cell types in concert with modulation of the chemical and mechanical cues found in a cancer-promoting microenvironment.
There are frequent gene copy number variations in breast tumors (490%), and the patterns of these variations are thought to be characteristic of different genetic pathways to tumorigenesis and to predict clinical outcome. Cytogenetic analysis using comparative genomic hybridization revealed amplification of the 17q22-24 chromosomal region in 18% of breast cancer cell lines and in 15-28% of primary breast tumors. [72] [73] [74] [75] This amplification appeared to be more common in high-grade tumors. 76, 77 Extensive analysis of this region in primary breast tumors has shown that the amplified 17q23 region contains several putative oncogenes, including RPS6KB1, RAD51C, APPBP2, SIGMA1B and TBX2. [78] [79] [80] Use of microarray and quantitative PCR approaches to analyze genes that are both amplified and overexpressed in breast cancer cells linked the PPM1D (Wip1) gene to the minimal 17q23.2 amplified region, which was found in 11.3-16% of primary breast tumors. Further, the level of Wip1 expression correlated positively with gene amplification. 30, 32 This positive correlation was confirmed in a series of studies of different types of primary breast tumors. 31, 33, 34, 81 It is worth noting, however, that further analysis revealed that overexpression of PPM1D in breast tumors is more prevalent than gene amplification (25% versus 13-15% of cases, respectively). 26 This could be because the relative abundance of proteins may not necessarily be proportional to their relative mRNA levels, so their levels can only be predicted in part by the relative mRNA abundance in human cell lines. Furthermore, the amount of Wip1 protein in tumors was much higher than the transcript levels, suggesting additional mechanisms for PPMD1 regulation at the protein level. 82, 83 These mechanisms could include posttranslational modifications as well as the regulation of protein degradation and are currently unknown.
Analysis of a larger set of breast tumor samples with PPM1D amplification revealed that all cases showed a 'firestorm' pattern of amplification that was characterized by multiple clustered highlevel amplifications on chromosomes 1, 8 and 17. 84 This pattern was highly correlated with the aggressive disease progression and poor survival, even when the rest of the genome was relatively unaltered. 84 PPM1D gene amplification is frequently associated with amplification of another locus, 17q12, which contains the Erbb2 oncogene, a well-known prognostic indicator in breast cancer. [85] [86] [87] There is ample evidence that there are multiple separate amplicons along the q-arm of chromosome 17 in breast cancer and that the Erbb2 and the PPM1D amplicons are indeed distinct. Observation of the association between PPM1D amplification and Erbb2 overexpression suggests that Erbb2 activation and PPM1D activation are two separate events that potentially act together in breast cancer development. 77, 88, 89 As increased Her2 protein levels stimulate growth-factor signaling pathways and drive cell proliferation, tumors with Erbb2 amplification (Her2+ tumors) are associated with advanced stages of cancer, tumor recurrence and poor patient survival. [90] [91] [92] Univariate survival analyses have failed to show a consistent association between PPM1D gene amplification or overexpression with disease-free, metastasis-free or overall survival. 26, 33 This could reflect the complexity of this association and the need for multivariate analysis. In familial breast tumors, on the other hand, co-amplification of the 8q21-23 and 17q22-25 regions are associated with highly aggressive tumors and poor prognosis. 93 It was shown more recently that amplified genes located on chromosomal regions 17q12, 17q21.33-q25.1, 8p11.2 and 8q24.3 can be used as independent markers of poor outcome that is associated with early relapse in ER-positive breast cancers treated with tamoxifen. 94 Recent gene expression-based classifications (PAM50) identified five 'intrinsic' breast cancer subtypes. Of these five subtypes, two are luminal-cell related (luminal A and luminal B), one is myoepithelial-cell related (basal like), one resembles normal breast tissue (normal like) and one is Her2 enriched. [95] [96] [97] Genome-wide correlation analysis of amplifications in different subgroups of breast cancers with matched-gene expression data led to the identification of PPM1D within a putative driver amplicon in a subgroup of breast tumors with poor prognosis. This subgroup of tumors is Her2 enriched or has the luminal B phenotype (Figure 1 ). Interestingly, PPM1D gene amplification was not observed, and its expression was significantly lower in basallike cancers. [98] [99] [100] Genome-wide integrated classification of breast cancers based on clustering analysis of joint copy number and gene expression data from cis-associated genes revealed 10 novel molecular subgroups. Amplification of 17q23, which contains PPM1D, is found in a specific integrative cluster of tumors, termed IntClust 1, which is characterized by relatively high levels of genomic instability and an intermediate prognosis ( Figure 1 ). Notably, IntClust 1 tumors show the highest prevalence of mutations in GATA3, the essential regulator of luminal-cell differentiation, and this distinguishes IntClust 1 tumors from other ER-positive tumors that were previously grouped together within the luminal B intrinsic subtype. 101, 102 Thus, independent analyses link PPM1D amplification and overexpression in breast tumors with unfavorable prognosis, suggesting a positive regulatory role for PPM1D in tumor development, especially in the luminal B breast cancer subtype.
In addition to gene amplification and overexpression, potentially cancer-driving mutations have recently been identified in the PPM1D gene. In primary human cancers, PPM1D mutations were found most frequently in uterine corpus endometrioid carcinoma (4.4%), followed by lung adenocarcinoma (2.2%), renal carcinoma (1.8%), colon, rectum adenocarcinoma (1.8%), stomach adenocarcinoma (1.7%) and thyroid carcinoma (1.5%); PPM1D mutations were also found at a o 1% frequency in some other types of cancer. 53 However, overall the incidence of PPM1D mutations in breast cancer is extremely low, and around 0.5%. Despite the rare incidence of mutations in the PPM1D gene in breast tumors, 18 protein-truncated variants were found in lymphocyte DNA from 6912 breast cancer patients. 54 Interestingly, all of the identified mutations led to proteins that were truncated in the C-terminal domain of Wip1; the truncations were downstream of a phosphatase catalytic domain but preceded or disrupted the putative nuclear localization signal. The PPM1D-mutant allele was less common than the wild-type allele, suggesting that the mutations were mosaic in lymphocyte DNA. Two of the identified mutations, Q462X and L395X, exhibited enhanced suppression of p53 in response to ionizing radiation. Surprisingly, the mutations identified in lymphocyte DNA were not found in tumor cells but rather in the surrounding tumor stromal tissue, which probably contained infiltrated lymphocytes. The authors suggested several possible explanations. First, an ancient PPM1D mutation may have been present during the initiation of tumorigenesis with a subsequent loss of the mutated allele in tumor progression. This is consistent with the loss in this region of 17q, which is frequently seen in breast cancer samples. Alternatively, the PPM1D mutation could be absent in tumor cells because oncogenesis is driven by paracrine factors associated with the mutations in the tumor environment. The predisposition to cancer development in heterologous cell types in carriers of PPM1D mutations is not well understood, and additional studies are needed to explain the mechanisms underlying oncogenesis. Mutation of PPM1D may represent an unusual and novel genetic risk factor for general cancer predisposition that is not associated with a single specific cancer type. This notion is supported by the observation that mutations occur in a discrete part of the PPM1D gene, by the variable onset of cancer in affected individuals, and by the broad spectrum of cancer types in mutation carriers and cancer cell lines. This predisposition could be different from the association of cancer with PPM1D amplification that is described above.
Analysis of the C-terminal truncating mutations (L450X, R458X and E585X) of PPM1D found in colorectal (HCT116), osteosarcoma cell lines (U2OS) and primary uterine corpus endometrioid carcinoma showed that truncated forms of the Wip1 have increased stability and preserved enzymatic activity. 52 This, in turn, suggested that this type of mutations might represent a gain of function. An important exception is the frequently found R552X-truncating mutation, which is a loss-of-function mutation that is associated with decreased protein stability. 53 These observations emphasize the need for further investigation of truncating mutations in PPM1D in tumorigenesis as well as careful interpretation of their functions.
To summarize, there is increasing evidence that PPM1D is an oncogene. Specifically, mutations in the PPM1D gene in cancer patients and breast cancer cell lines are heterozygous, and protein-truncating gain-of-function mutations have been identified in PPM1D. Further, Wip1 is frequently overexpressed and amplified in tumors and has regulatory functions in the tumor suppressor Atm-Chk2-p53 and p38 MAPK-Arf/p16Ink4a signaling Figure 1 . Classification of Wip1 amplifications in breast cancer. Wip1 is amplified in different intrinsic subtypes of breast cancer based on PAM50 molecular profile. 97 The majority of Wip1 amplifications is present in Luminal A and B intrinsic subtypes. Amplification of Wip1 are also associated with defined integrated clusters based on genome-driven integration classification of breast tumors. 69 The majority of Wip1 amplifications is present in IntClust 1. On the basis of these classifications, Wip1 amplification and overexpression can be potentially used to define particular subtypes of breast cancer. Relative distribution of tumors with Wip1 amplifications among different subtypes or clusters is shown. For more details see text. pathways further supporting the role of PPM1D as an oncogene (Figure 2 ).
WIP1 IN ERBB2-DRIVEN BREAST CANCER
The oncogenic features of Wip1 were first demonstrated in mouse embryo fibroblasts based on cooperation assays with other oncogenes, including Erbb2, in the induction of anchorageindependent growth. 30 Overexpression of PPM1D in IMR-90 human lung fibroblast cells abrogates p53 phosphorylation at serine 33 and serine 46 through the inhibition of p38 MAPK activity, which protects cells from oncogene-induced apoptosis and partially prevents cell cycle arrest. 30 In addition, overexpression of Wip1 can abrogate Ras-induced senescence in primary cells and can prevent apoptosis induced by serum starvation. 32 However, transformation assays with p53-deficient fibroblasts revealed that although the HrasV12, Erbb2 and Myc oncogenes individually transformed cells, Ppm1d alone did not, suggesting that it is a rather weak oncogene. 30 Subsequent studies with knockout mice showed that Ppm1d-deficient mouse embryo fibroblasts have a profound resistance to transformation when they are engineered to express oncogenes, including Erbb2, even in the absence of p53. 30, 32 Increasing evidence suggests that the target cell type for transformation in the MMTV-neu model belongs to the alveolar lineage. Lineage tracing using a whey acidic protein -promoterdriven Cre recombinase together with a Rosa-lox-stop-lox-LacZ reporter showed that early lesions in MMTV-neu mammary glands are all LacZ-positive, indicating that these cells express milk genes at some point. These LacZ-marked cells are also referred to as parity-identified mammary epithelial cells (PI-MECs) or lobulerestricted progenitors. 103 Strikingly, mice with a cyclin D1 point mutation have normal mammary ducts but appear to lack PI-MECs. Importantly, mice with the cyclin D1 point mutant as well as cyclin D1 knockout mice are completely resistant to MMTVneu tumorigenesis. 104, 105 Similarly, Ppm1d − / − mice are resistant to mammary tumor development driven by MMTV-Erbb2. 25 Although the effect of Ppm1d deficiency on PI-MECs has not been investigated, enhanced expression of both p16 and p19 through activation of p38 MAPK was shown to contribute to the transformation-resistant phenotypes of Ppm1d-deficient mice. In turn, when Ppm1d − / − /MMTV-Erbb2 mice are treated with SB203580, a specific p38 MAPK inhibitor, the tumor-resistant phenotype is reversed, presumably by downregulation of p16 expression in mammary gland tissues. 25 These results indicate that Ppm1d is oncogenic in the mammary gland, at least in the context of Erbb2-driven tumorigenesis, as the result of its ability to inhibit the tumor suppressor pathways guided by p53 and p38 MAPK. 25 More than 30% of breast tumors with PPM1D amplifications show co-amplification of the ERBB2 oncogene. Together with the results of tumorigenicity assays in mouse embryo fibroblasts this suggests that these genes may act cooperatively in breast tumor development. To study this function in vivo, we established a transgenic mouse model in which Ppm1d is expressed in mammary gland epithelium under the control of the MMTV promoter. 106 No spontaneous tumors emerged during the life spans of these mice, nor did they show noticeable abnormalities in mammary gland development. However, in double-transgenic mice that overexpress both Ppm1d and Erbb2 in mammary epithelial cells under the control of the MMTV promoter, the onset of breast tumors is accelerated compared with the onset in transgenic MMTV-Erbb2 mice. The cooperative effect of Ppm1d and Erbb2 in enhancing mammary cell proliferation and accelerating tumor development is reversed by the activation of Mkk6-p38 MAPK-p16/Cdkn2A signaling pathway. 106 Importantly, 42% of human breast tumors with Wip1 overexpression show decreased p16 expression, further supporting a role for Wip1 in a linear pathway with Cdkn2a/p16. 26 In epithelial cells, repression of p16 increases the expression of chromatinremodeling proteins such as EZH2 and SUZ12 that are important for the epigenetic plasticity underlying differentiation. 107 Recently, based on an analysis of surface markers induced by p16 repression, a rare somatic cell population (ePS cells) was isolated from normal human breast tissue. 108 These ePS cells exhibited remarkable lineage plasticity. The observation that repressed p16 levels link epigenetic and phenotypic plasticity, plus the involvement of PPM1D in the regulation of CDKN4A locus activity, may suggest that Wip1 has a functional role in the regulation of plasticity states of cells during mammary gland tumorigenesis, including in the regulation of cancer stem cell properties.
WIP1 IN WNT-DRIVEN BREAST CANCER
HrasV12-, Erbb2-and myc-but not Wnt1-driven mammary gland tumorigenesis is reduced in the absence of Ppmd1. 25 It has been suggested that pathways that are activated or inhibited in the absence of Ppm1d cannot protect mammary cells from Wnt1driven oncogenesis. These results are somewhat surprising in light of recent findings that Wip1 deficiency negatively regulates Wnt signaling by inducing the expression of the Wnt antagonist, Dkk3 109 (Figure 2 ). This in turn may suggest that neither overexpression of Dkk3 nor upregulation of p53 (which is generally observed in Wip1-deficient mice) is sufficient to overcome MMTV-Wnt-driven tumorigenesis.
In patients with breast cancer, gene mutations that directly activate Wnt are generally uncommon, though found in a few rare metaplastic breast cancer cases. 110, 111 Circumstantial evidence in patients with triple-negative and basal-type breast cancers suggests the activation of the Wnt pathway, which is most likely induced by the interaction of cancer cells with their microenvironment. 112, 113 Mammary tumors in MMTV-Wnt1 transgenic mice are histologically heterogeneous, containing multiple cell lineages within a single tumor. Unlike tumors in other mouse models, these tumors contain discrete populations of tumorinitiating cells. [114] [115] [116] Because of this, pre-neoplastic mammary tissue in MMTV-Wnt1 mice is highly enriched with stem/ progenitor-like cells, including the mammary stem cell-enriched basal cell population. This is consistent with the fact that stem or progenitor cells that are part of the basal layer are the cells that are most likely to be sensitive to transformation by Wnt1. [117] [118] [119] In contrast, Wip1 is thought to primarily affect the luminal compartment of the mammary gland, including a role in the regulation of hormone-sensing cells, 67 which could partially explain why Wip1 deficiency does not inhibit Wnt-driven mammary gland tumorigenesis in mice.
WIP1 AND BRCA2-DRIVEN TUMORS
The 17q23 amplification that includes the PPM1D gene seems to be more common in tumors from BRCA1 or BRCA2 mutation carriers, suggesting that the PPM1D gene may have a cooperative effect with these mutations in the development of human breast cancer. 79 Studies report that BRCA1-and BRCA2-driven tumors have distinct molecular phenotypes: BRCA1 tumors are predominantly ER negative with basal-like features, whereas BRCA2 tumors are predominantly ER positive and develop into luminal-like tumors. Several studies have shown that human BRCA2-mutated tumors resemble sporadic tumors and do not skew towards any phenotype, whereas 90% of human BRCA1-mutated tumors have a basal-like phenotype. [120] [121] [122] Despite the normal development of mammary tissue in Brca2deficient mice, most of the female mice develop spontaneous non-metastatic mammary carcinomas as well as adenosquamous carcinomas after a long latency. 123 The tumors are aneuploid, with chromosomal aberrations and acquired p53 mutations. Homozygous deletion or loss of heterozygosity of p53 significantly Wip1 phosphatase in breast cancer A Emelyanov and DV Bulavin accelerates tumor development. Interestingly, most sporadic mammary gland tumors in p53-knockout mice are a mix of basal carcinomas and carcinosarcomas, whereas Brca2/p53-knockout tumors are mainly basal-like adenocarcinomas. The morphological appearance of the mammary tumors varies from matrix-producing carcinomas to biphasic tumors with luminal and myoepithelial differentiations, and, occasionally, sarcomatoid spindle cell carcinomas. [123] [124] [125] Although Wip1 overexpression complements the Erbb2 oncogene in mammary gland tumor development, this cooperative effect is not observed in tumor models with conditionallydeficient Brca2. 106 The development of Brca2-mutated tumors is not accelerated upon overexpression of Wip1; this could be because Wip1 has tumor-type specific oncogenic properties, and its effects are mainly restricted to a subset of luminal-type tumors. Unfortunately, several mouse models, including the Brca2 mammary tumor mouse models, develop mammary tumors with histopathological features that are rather different from their human counterparts. Whether this reflects differences in the cellof-origin or more general species-based differences remains unclear. Although Wip1 overexpression does not accelerate BRCA2-driven tumorigenesis in mice, the inhibitory effect of Wip1 on Tp53 activity may change the histological profile of the developed tumors. This aspect has not been investigated but would help us better understand the importance of Wip1 as an oncogene in mammary gland tumorigenesis.
WIP1 AND P53
Despite the fact that almost 30% of human breast cancers carry p53 mutations, reports suggest that these tumors rarely contain PPM1D amplifications. 30 Further, most breast tumors with PPM1D amplifications show no structural changes in the p53 gene. 30 This could be because PPM1D overexpression functionally inhibits p53, directly or indirectly, by regulating its phosphorylation status, thus protecting the cells from oncogene-induced apoptosis and cell cycle arrest. This in turn may remove selective pressure to inactivate p53 through the induction of mutations during tumor evolution. Similarly, human cancers in which the CDKN2A locus is silenced through hypermethylation or deletion, 126 as well as tumors with MDM2 amplification, also show structurally wild-type p53. 127, 128 More recently, however, due to accumulating tumor genome sequencing data in TCGA studies, p53 mutations have been found in breast tumor samples that also show PPM1D amplification or overexpression. Exome-sequencing analysis of 1420 breast tumor samples revealed a loss of heterozygosity and the presence of p53 mutations in more than 20% of luminal B breast cancers (IntClast1), the majority of which contained either amplified or overexpressed Wip1. This subset of tumors was found in patients with the worst outcomes. 129 Although the presence of Wip1 amplification and p53 mutations in the same cancer cells still needs to be verified, these data suggest that excess of PPM1D in tumors through decreased selective pressure may slow, but not abolish, the formation of p53 mutations during tumor progression.
Although p53 is structurally unaltered in many breast cancers, p53 is thought to be functionally inactivated through multiple mechanisms including PPM1D amplification and overexpression. It was found that among p53 wild-type tumors, as much as 37% of the Wip1-overexpressed cancers have high scores for the embryonic stem cell signature. 130 These data suggest that overexpression of Wip1 through inactivation of p53 or potentially other mechanisms, may create a permissive environment for the generation of tumor cells with stem cell-like transcriptional profiles. Such a state could explain why tumor cells exhibit remarkable plasticity, acquiring cancer stem cell properties and chemoresistance in the course of cancer therapy. 131 This, in turn, may suggest that Wip1 has important roles in regulating the sensitivity to cancer treatment and in the development of tumor relapse.
The involvement of Wip1 in cancer cell chemoresistance was demonstrated recently in a number of studies that suggested that Wip1 inactivation sensitizes cancer cells to chemotherapy by regulating p53-dependent apoptosis. [132] [133] [134] Specifically, the downregulation of Wip1 enhanced cisplatin chemosensitivity in the osteosarcoma cell line U2OS and in the colon cancer cell line HCT116 (both of which carry WT p53 alleles). 135 However, Wip1 downregulation had no impact on cisplatin sensitivity in HCT116 p53 − / − cells or in the p53-negative osteosarcoma cell line Saos-2. 135 Downregulation of Wip1 by anti-sense RNA in the MCF-7 breast tumor cell line also enhanced doxorubicin-induced apoptosis through p53-regulated activation of Bax. 134 Furthermore, efficient downregulation of PPM1D using siRNA resulted in significantly reduced cell proliferation in MCF-7 and ZR-75-1 cells with wild-type p53 alleles but not in BT-474 cells, which have mutant p53. This indicates that the anti-proliferative effect of PPM1D silencing is dependent on the p53 status. 136 In a panel of PPM1D-amplified and non-amplified human tumor cell lines, silencing PPM1D with RNAi and inhibiting PPM1D with the chemical CCT007093 showed that PPM1D is selectively required for the survival of cells with PPM1D gene amplifications. 137 This suggests a Wip1 oncogene addiction for these cancer cells. Taken together, these data suggest that in the majority of cases, the effect of Wip1 downregulation or inactivation on the negative regulation of cancer cell proliferation and survival depends on the presence of wild-type p53.
In many cases, downregulation of Wip1 in p53-deficient or p53mutant cell lines does not have a significant impact on cell viability. In contrast, recent studies suggest that Wip1 overexpression or activation may have some therapeutic value. Specifically, overexpression of Wip1 in p53-negative Saos-2 tumor cell lines sensitizes them to cisplatin via Runx2-dependent transcriptional activation of the pro-apoptotic BAX gene. 138 Importantly, a transgenic mouse line that overexpresses Wip1 shows significantly less cisplatin-induced intestinal damage compared with wild-type mice. The authors suggest that Wip1 overexpression could act as a double-edged sword by protecting normal cells in the course of chemo or radiotherapy, whereas at the same time sensitizing p53-deficient cancer cells to apoptosis. 135, 138 WIP1, HETEROCHROMATIN AND MUTAGENESIS IN BREAST CANCER Sequencing analysis of primary [139] [140] [141] tumors shows that several types of mutagenesis processes occur in breast cancers. One is related to the formation of regional hypermutations or 'kataegis,' which often occur at the site of genomic rearrangements. 142, 143 Most of the mutations in kataegis are C4T and C4G substitutions flanked by a 5′-T. These mutations are attributed to cytosine deamination and mainly occur in cis across the same parental chromosome. Some of these mutations correlate with complex somatic rearrangements. 144 Such hypermutations are likely generated by members of the APOBEC family of proteins. 145, 146 The DNA cytosine deaminase APOBEC3B has recently been suggested to be a driver of mutations, especially C-to-T and C-to-G substitutions at TC motifs with non-methylated cytosines. 147 Notably, APOBEC3B is overexpressed in cell lines and breast tumors with p53 mutations. High APOBEC3B expression levels are associated with p53 mutations and mostly with basal-like tumors, suggesting that different mechanisms contribute to p53 mutagenesis. 129 In addition to formation of regional hypermutations, analysis of gene copy number alterations in mammary gland cancers identified 'firestorms' of local amplifications and deletions whose origin is uncertain but which could be the result of breakage-fusion-bridge cycles. 84 We recently found that the Wip1 expression level positively correlates with a burden of mutations and with the rate of C-to-T substitutions in primary breast cancers 29 (Figure 3 ). In addition, overexpression of Wip1 leads to increased H3K4-trimethylation that could provide a docking site for cytidine deaminases, which catalyze the deamination of cytosine to form uracil. Under conditions in which Wip1 is overexpressed, leading to inhibition of the DNA repair machinery, the majority of the incorporated uracil remains unrepaired, generating new point mutations. 29 Interestingly, Wip1 amplifications are more abundant in luminal B type tumors, whereas overexpression of Aid/APOBEC is not typical for this subtype. This suggests potential mutual exclusivity. These findings further suggest that there are alternative mechanisms of mutagenesis in breast tumors of different origin.
Recruitment of Aid to DNA in response to Wip1 overexpression, as well as through other mechanisms, could lead to chromosomal translocations caused by rearrangement of non-homologous chromosomes. Specifically, it was shown that Aid activity is required for the formation of DNA breaks in the c-MYC gene before the formation of MYC-IGH translocations in Burkitt's lymphoma. 148 The finding that Aid is a critical factor in the formation of translocations raises the possibility that Wip1dependent Aid regulation is a general translocation factor and could be a player in the formation of translocations including those in breast tumors.
We recently found that Wip1 overexpression leads to derepression of GC-rich heterochromatic sequences, including LINE-1 (L1) and HERV, by regulating the recruitment of Brca1 and Dnmt3b to DNA (Figure 3 ). 29 Furthermore, Wip1 inhibition leads to changes in genome methylation landscapes and to silencing of heterochromatin-associated retroelements. 29 L1 retrotransposon activity can cause diseases by insertional mutagenesis, by recombination, by providing enzymatic activities for other non-long terminal repeat retrotransposons, and perhaps by transcriptional overactivation and epigenetic effects. Since the discovery of L1 elements as mutagenic insertions, 96 diseasecausing mutations in humans have been attributed to L1-mediated retrotransposition events. 149, 150 Recent reports also suggest that L1 endonuclease may have a general function in facilitating chromosomal breaks and genome instability. [151] [152] [153] However, somatic L1-related rearrangements that have driven tumorigenesis have rarely been observed in humans. Before 2010, only two such cases had been reported. The first case involved a gene-activating rearrangement at the Myc oncogene locus in breast ductal adenocarcinoma, and the second case involved a newly integrated L1 sequence that inactivated the APC tumor suppressor gene in colon cancer cells. 154, 155 The introduction of targeted next-generation sequencing and development of additional methods in recent years led to the identification of somatic L1 retrotranspositions in colon, lung, prostate and ovarian cancers, as well as in mammary gland tumors. [156] [157] [158] The fact that the somatic insertions are skewed toward genes that are commonly downregulated or mutated in the tumors suggests that L1 insertions may contribute to cancer formation, whereas epigenetic deregulation of L1 sequences may promote transcription of nearby oncogenes. 159, 160 Activation of transcript variants initiated by L1 promoters in bladder carcinoma, chronic myeloid leukemia, esophageal adenocarcinoma and breast carcinoma has also been reported. 161, 162 The malignant phenotype is inherently associated with both global and tumor-specific methylation changes, and transposable elements comprise the majority of the human genome. 163 Accordingly, it is difficult to determine the role of transposon demethylation per se in tumorigenesis, especially without functional studies. It is possible that pathogenic cellular stress responses, including those regulated by Wip1, could result in local or global transposon deregulation, for example, via demethylation or chromatin modifications. Such epigenetic deregulation might result in single or multiple retrotransposition events. Considered together, recent data suggest a new role for Wip1 in mutagenesis processes and cancer evolution through modulation of the chromatin state of tumor cells. Transcriptional activation of retrotransposons when Wip1 is overexpressed may suggest an additional mechanism of Wip1-directed mutagenesis, that is, regulation of the expression and activity of retroelements, including L1.
The ways in which the biology of mammary epithelial cell subtypes shape the behavior of mammary cancers remain elusive owing to the complexity of multistep tumor progression. Although mammary glands were initially thought to include relatively few cell types, the number of cell types has expanded in recent years. Development of lineage-specific markers and in vitro functional assays has enabled the isolation of discrete subpopulations of epithelial progenitors, multi-and unipotent stem cells. [164] [165] [166] [167] The existence of multiple cell types in mammary glands makes it difficult to identify the cell of origin for a particular subtype of breast cancer and also makes it difficult to determine how the different cell types impact tumor initiation and progression. These difficulties have important implications for strategies to treat mammary gland tumors. For example, recent reports caution against assuming that breast cancers faithfully maintain the biologic features of their cells of origin. Both human and mouse studies suggest that basal-type breast cancers may arise from a luminal progenitor in BRCA2/1 familial breast cancers. 168, 169 In this context, it is important to point out that the ability of Wip1 overexpression to accelerate tumorigenesis or the ability of Wip1 inactivation/deletion to suppress tumorigenesis may be cell-or tumor-type specific in the mammary gland. Wip1 involvement is attributed to the luminal type of cancers; thus, these tumors should be considered as the primary targets for Wip1-specific therapies.
